Biljana Naumovic is President, U.S. Solid Tumor. In this role, she leads one of the company’s fastest growing therapeutic areas and advances the organization’s solid tumor portfolio and pipeline, spanning prostate cancer, bladder cancer, and lung cancer, as well as multiple novel tumor pathways. Biljana is a member of the Johnson & Johnson Innovative Medicine North America Leadership Team.
Prior to this role, Biljana was Worldwide Vice President, Global Commercial Strategy, Oncology for the Janssen Pharmaceutical Companies of Johnson & Johnson. Working in collaboration with the R&D organization, she led the development of breakthrough commercial strategies to deliver a sustainable and differentiated oncology pipeline.
Biljana has also held the position of Managing Director, Janssen Australia & New Zealand (Janssen-Cilag Pty Ltd.) where she oversaw a cultural transformation and reorganization of the business, culminating in double digit growth in 2021. Biljana first joined Johnson & Johnson in 2019 as Vice President, Oncology for Europe, the Middle East and Africa (EMEA), where she created and delivered the commercial strategy across the solid tumor portfolio and pipeline for the region.
